Table 1.
Patient Characteristics
| Characteristic | No. of Patients | % | |
|---|---|---|---|
| Sex | |||
| Male | 22 | 56.4 | |
| Female | 17 | 43.6 | |
| Age, years | |||
| Median | 62 | ||
| Range | 42–84 | ||
| Tumor histology | |||
| Colorectal cancer | 14 | 35.9 | |
| Melanoma | 10 | 25.6 | |
| Prostate cancer | 8 | 20.5 | |
| NSCLC | 6 | 15.4 | |
| Renal cell carcinoma | 1 | 2.6 | |
| ECOG PS | |||
| 0 | 13 | 33.3 | |
| 1 | 26 | 66.7 | |
| Prior therapies | |||
| Median | 4 | ||
| Range | 1–13 | ||
| Chemotherapy* | 36 | 92.3 | |
| Radiation therapy | 13 | 33.3 | |
| Surgery | 39 | 100 | |
| Immunotherapy | 14 | 35.9 | |
| Biologics† | 26 | 66.7 | |
| Hormonal therapy | 8 | 20.5 | |
Abbreviations: NSCLC, non–small-cell lung cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status.
*
Includes molecularly targeted therapies.
†
Includes monoclonal antibody therapies.